Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516265 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Electronic (PDF)Add to Basket
EnterprisewideAdd to Basket
Live Chat Live Help Software for Website

Stakeholder Opinions: Tropical Diseases - Dengue, Japanese encephalitis and West Nile virus - Increasing attention for neglected diseases

Datamonitor, Dec 2010, Pages: 204


  Description  
   Table of Contents   
    
    
    
     
  Enquire before Buying   
  Send to a Friend   

Dengue, Japanese encephalitis and West Nile virus are major causes of disease worldwide. Dual market pricing strategies for endemic countries and the Western travelers market offer great commercial opportunities for dengue and Japanese encephalitis vaccines. In contrast, low incidence makes West Nile a less commercially attractive target.

Scope of this research

- Discussion of market environment for dengue, Japanese encephalitis and West Nile in US, 5EU and Japan, as well as the rest of the world
- Thorough assessments of key marketed vaccines and therapeutics, as well as pipeline products
- Epidemiology section discussing key epidemiological features of disease caused by dengue, Japanese encephalitis and West Nile Detailed background information on dengue, Japanese encephalitis and West Nile, including diagnostics, disease burden and potential drug targets

Research and analysis highlights

Although a high disease burden and the spread of dengue make vaccination attractive in selected target groups, uptake in the 7MM will remain limited due to a lack of reimbursement structures.

The JE vaccine SA-14-14-2 (Chengdu) remains the first choice vaccine in many endemic regions. In the US and Europe, Intercell's Ixiaro is now the preferred vaccine for military personnel and travelers. However, a low risk for travelers and out-of-pocket payment for travelers vaccines will limit its commercial potential in the 7MM.

Although West Nile virus has become endemic in the US and several European countries in the last decade, low overall incidence is a big obstacle for the development of antivirals and vaccines, as it complicates clinical trial design and limits commercial prospects.

Key reasons to purchase this research

- Review vaccine and antiviral development progress, pipelines and success factors in dengue, JE and West Nile
- Understand challenges, unmet needs and future opportunities by learning about the views of industry and academic key opinion leaders
- Understand the epidemiology of dengue, Japanese encephalitis and West Nile virus in the seven major markets and its impact on commercial opportunities



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-800-526-8630 (US/Canada Toll Free)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds